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ABSTRACT OF DISSERTATION 
THE SELF-REPORTED AND BEHAVIORAL EFFECTS OF PROPYLENE GLYCOL 
AND VEGETABLE GLYCERIN IN ELECTRONIC CIGARETTE LIQUIDS 
Little is known about how electronic cigarette (EC) users manipulate device 
parameters, what factors drive their use, and how non-nicotine ingredients influence the 
stimulus effects of EC aerosols. The ingredients propylene glycol (PG) or vegetable 
glycerin (VG) serve as the base for virtually all electronic cigarette liquids, and 
information on how they affect the using experience would provide important 
groundwork for the study of other ingredients. In this dissertation, results from a survey 
and laboratory study focused on the stimulus effects of ECs, and the influence of PG and 
VG, will be discussed. A total of 522 regular EC users completed a survey comprised of 
an electronic cigarette dependence questionnaire, questions on tobacco and electronic 
cigarette use, and device and liquid preferences.  This was followed by a laboratory study 
with sixteen electronic cigarette users completing five test days (one practice and four 
assessment days). In the laboratory study, following one hour of nicotine deprivation, two 
sampling puffs from liquid formulations containing 100/0, 75/25, 50/50, 25/75, and 
0/100% PG/VG concentrations were administered in random order during five 
assessments, each separated by 20 min. Primary outcome measures were self-reported 
stimulus characteristics and breakpoint on a multiple-choice procedure. Survey results 
indicated that ability to change device voltage, and level of resistance, was significantly 
associated with level of nicotine dependence, as was amount of liquid consumed, nicotine 
concentration, and milligrams of nicotine used per week. Participants also rated 'good 
taste' as the most important consideration when purchasing and using liquids, and PG was 
associated with undesirable effects and VG with desirable effects. Laboratory results 
indicated that greater VG content was associated with greater reports of visibility of the 
exhalant (i.e. “cloud”). Liquids with mixtures of PG or VG were associated with 
conventional cigarette smoking sensations and greater reductions of systolic blood 
pressure compared to formulations with only PG or VG. There was no significant effect 
of liquid formulation on the multiple-choice procedure, but puffs were rarely chosen over 
even the smallest monetary option ($0.05), suggesting minimal reinforcing efficacy.  In 
conclusion, survey data indicate that a wide range device parameter settings and liquid 
ingredients are preferred by daily e-cigarette users, and that individuals with greater 
nicotine dependence favor voltage control devices, and lower resistance heating 
elements.  Survey data also indicated that taste is a key factor for EC liquid selection, and 
relative concentrations of propylene glycol and vegetable glycerin may have a significant 
impact on the reinforcing effects of liquids.  In contrast, laboratory data suggests that PG 
or VG do not significantly impact the abuse liability of EC liquids, though reinforcing 
effects of these ingredients was unclear in the laboratory study.   
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CHAPTER ONE: ABUSE LIABILITY OF ELECTRONIC CIGARETTES 
1.1 Introduction to Abuse Liability and Electronic Cigarettes 
In the following dissertation the abuse liability of electronic cigarettes (EC) will 
be discussed.  First, it is necessary to define abuse liability.  Previous definitions of abuse 
liability have divided it into two sub-parts: “liability for abuse” and “liability of abuse” 
(Griffiths et al., 1987).  Liability for abuse refers to the likelihood that a drug will be used 
for non-medical reasons – either as any use of a drug, or use of a medically prescribed 
drug in excess.  Liability of abuse refers to the undesirable aspects of drug use (e.g. 
physical or social consequences to the user).  
Predicting abuse liability of a drug is critical for assessing likelihood of abuse or 
off-label usage of therapeutic drugs before or after they go to market, and to determine 
the mechanisms driving misuse of drugs to facilitate development of treatment or 
regulatory approaches to lessen the negative impacts of drug abuse.  Drug abuse liability 
is commonly assessed by examining human behavior in a laboratory setting.  When 
examining abuse liability in a laboratory setting it is important to ensure proper control of 
experimental conditions, such as: presence of non-study psychoactive drugs, participant 
nutrient levels, and other variables that may influence study outcomes (Griffiths et al., 
2003).  As with the study of therapeutic drugs, it is also important to control for 
participant and experimenter expectations by using double-blind placebo-controlled study 
design.  With nicotine and other drugs, consideration of drug use history requires careful 
consideration; withdrawal, for example, may alter a drug’s abuse liability.  Individuals 
who are experiencing withdrawal from a drug will likely respond differently on abuse 
liability measures compared to when they are not experiencing withdrawal symptoms 
 2 
(e.g. Bell et al., 1999).  As such, it is necessary to measure withdrawal symptoms, which 
can be drug specific, in order to capture possible influence of withdrawal alleviation on 
abuse liability. 
Several types of outcome measures are typically used to assess a drug’s abuse 
liability in a laboratory setting.  Measures can include subject ratings related to likelihood 
for the drug to be abused.  Such ratings are often input by study participants using a 
visual analog scale and can include items associated with drug liking or desire to use the 
drug again.  To assess liability of abuse, subject-ratings focused on potentially 
undesirable effects (e.g. nausea, anxiety, “bad-effects”) are typically incorporated.  To 
assess liability for abuse, ratings focused on potentially desirable effects (e.g. feeling 
“high” or experiencing a “good effect”) are often used.  More direct measures of drug 
taking behavior are also typically incorporated.  These can include self-administration 
paradigms that require the participant to enter responses in order to receive additional 
drug (for review see Panlilio and Goldberg, 2007), or decision-making paradigms that 
require the participant to choose between the drug being studied and a reference alternate 
reinforcer with a well characterized value (e.g. money or a drug with well-characterized 
abuse liability) (e.g. Griffiths et al., 1993).  Although it may often be the case that drug-
taking is associated with self-reports of desirable effects, these measures are not always 
concordant (i.e. if a given drug dose is particularly high, participants may report 
experiencing desirable effects while emitting fewer responses to receive more drug 
relative to a lower dose).  Therefore, comprehensive assessments of liability for abuse 
include direct measures of drug-taking behavior in addition to self-reported drug effects. 
In addition to the aforementioned measures, physiological measures such as heart rate 
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and blood pressure, and some indication of biological drug concentration (e.g. breath or 
plasma drug concentration), are typically collected to account for individual and between-
session differences in drug effects.    
Popularization of ECs is relatively recent, (the first largely successful EC was 
developed in China around 2005 [Lik, 2005]), and the first laboratory studies of EC abuse 
liability were published in 2010.  Although a new product, a long history of conventional 
cigarette (CC) research greatly informed early EC abuse liability work because of their 
shared inclusion of nicotine.  For example, CC’s engender well-characterized acute 
effects (Perkins et al., 1994), and tobacco deprivation among regular smokers 
consistently produces a common set of withdrawal symptoms (e.g. Hughes and 
Hatsukami, 1986).  Leveraging this history of CC research, in one of the first EC abuse 
liability studies Vansickel and colleagues (2010) assessed two early generation, low 
power, ECs in a population of CC smokers following 12 h of CC deprivation.  Abuse 
liability was measured by examining plasma nicotine concentration (nicotine being a 
drug with well documented abuse liability), and subject reports of drug liking and 
alleviation of CC withdrawal symptoms.  Interestingly, the results of this study did not 
indicate significant elevation of plasma nicotine concentration following use of these 
early generation ECs.  Yet, participants did indicate alleviation of some CC withdrawal 
symptoms – though to a lesser extent than a CC – suggesting that ECs would have some 
abuse liability among individuals experiencing CC withdrawal symptoms, perhaps by 
providing stimuli other than nicotine acting in the central nervous system (e.g. sensations 
associated with inhalation of nicotine or other stimulus effects associated with CC use).  
In a later study by Vansickel and colleagues (2012), abuse liability of ECs was assessed 
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among a sample of CC smokers – following 12 h of CC deprivation – using a decision-
making paradigm (the Multiple Choice Procedure), which offered participants the ability 
to choose between puffs from an EC or an amount of money.  Contrary to their earlier 
study, the EC now significantly increased plasma nicotine concentration.  Using a CC as 
a comparator, choices for 10 puffs from the EC in this study had a lower breakpoint 
(point at which money was chosen over puffs) than choices for three puffs from a CC 
($1.06 versus $1.50, respectively).  These data suggest that ECs have some abuse liability 
among CC users following CC deprivation, but perhaps less than CCs.   
 In a review of the scant literature on the abuse liability of ECs in 2013 that 
included the two previous studies, Evans and Hoffman (2014) noted that data on the 
abuse liability of ECs was inconsistent.  It was noted that a possible reason for this 
inconsistency is differences in history of EC use by participants in laboratory studies.  
Evans and Hoffman (2014) note that in studies measuring puff topography of ECs 
participants would inhale longer (i.e., longer puff duration), and ECs required more effort 
to draw air through compared to CCs.  Thus, it may be that individuals with no EC 
experience (e.g. only CC experience) must learn to account for differences in the 
inhalation aspects of CCs and ECs.  This possibility is supported by the lack of 
significant plasma nicotine increases among EC naïve participants in Vansickel et al. 
(2010), while experienced EC users have significantly increased plasma nicotine 
concentrations in other studies (e.g., Dawkins and Corcoran, 2014).  Another issue likely 
affecting consistency of study results is the wide variety of EC devices and their settings, 
as well as the large variety of liquids for ECs. 
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Taken together, the extant literature suggests that ECs can have abuse liability, as 
assessed by abuse liability measures successfully used to study other drugs of abuse.  
Because the abuse liability of CCs is well characterized in the natural ecology as a 
reinforcer that is often used despite many possible negative consequences, this 
comparator has provided a useful benchmark to compare ECs to in the laboratory.  
Research has not yet, however, examined the abuse liability of ECs among individuals 
with no CC history, making it difficult to know the independent abuse liability of ECs.  
Additionally, due to differences potentially caused by history of EC use (or lack therein), 
the inconsistency of laboratory results on EC abuse liability suggests that other factors 
need to be considered.  The following sections will outline some of these factors and 
how recent research has examined their influence on EC abuse liability.  
1.2 Effects of Liquid Nicotine Concentration 
Though perhaps not the only ingredient contributing to the reinforcing effects of 
CCs or tobacco more broadly, it has been well-known for decades that nicotine is a 
powerful reinforcer.  Documents from the tobacco industry dating back to as early as 1963 
indicate there has long been some awareness that “nicotine is addictive” (ASH, 1998).   
Converging evidence from laboratory studies over the past few decades have demonstrated 
that nicotine is a powerful reinforcer for animals and humans via multiple routes of 
administration (Stolerman and Jarvis, 1995).  With regards to nicotine in ECs, despite 
common availability of non-nicotine containing EC liquids (e.g., most specialty EC stores 
stock liquids for sampling which must not contain nicotine), recent data suggests that EC 
users are purchasing liquids that contain nicotine 99.0% of the time (Marynak et al., 2017), 
making it likely that nicotine is a primary factor in the liability for abuse of ECs.   
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As previously mentioned, research on the effects of nicotine in EC liquids has been 
mixed on whether they can deliver clinically significant amounts of nicotine.  Vansickel 
and colleagues (2010) examined two different types of early ECs containing 16 or 18 
mg/ml nicotine concentrations and found that 10 puff bouts did not significantly elevate 
plasma nicotine levels among EC naïve participants.  The use of these ECs did, however, 
reduce some subjective reports of tobacco abstinence, but to a lesser extent than a CC.  In a 
similar study, Bullen and colleagues (2010) found little increase of plasma nicotine among 
EC naïve individuals following 60-min ad-lib use of an EC with 16 mg/ml nicotine 
concentration.  In a later study by Vansickel and colleagues (2012), however, significant 
increases of plasma nicotine concentration were observed.  In this study ECs were 
administered to individuals with experience using ECs, with aerosol being dispensed from 
devices and liquids the participants provided, and nicotine concentrations ranging between 
9-24 mg/ml.  Following a 1 h ad-lib puffing period, plasma nicotine concentrations reached 
levels comparable to those achieved following CC use (i.e. mean=16.3 ng/ml).  As Evans 
and Hoffman (2014) point out, lack of experience with ECs may explain why the previous 
two studies did not find significant increases in plasma nicotine.  In Vansickel et al (2012), 
although several factors were changed relative to previous studies (e.g. device parameters, 
EC use experience, liquid nicotine concentration), it was proven that ECs are capable of 
providing significant levels of nicotine.  Later work has gone on to show that ECs are 
capable of increasing plasma nicotine to levels exceeding those typically observed 
following CC administration (Ramoa et al., 2015).  
Laboratory research has shown a positive correlation between nicotine 
concentration in EC liquids and the nicotine yield of EC aerosols (Talih et al., 2014), 
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suggesting there would be a dose dependent increase in plasma nicotine concentration as 
nicotine concentration in liquids is increased.  This has been demonstrated in laboratory 
studies examining multiple liquid nicotine concentrations, with pharmacokinetic delivery 
profiles closely resembling that of CCs (Ramoa et al., 2015; Lopez et al., 2016).  
Laboratory research on the behavioral effects of multiple nicotine concentrations in ECs 
has, however, been less clear.  Harvanko and colleagues (2017) examined behavioral 
effects of three liquid nicotine concentrations (0, 8, and 16 mg/ml) among non-regular EC 
users in a laboratory study with controlled puffing conditions (i.e. 10 five second puffs) and 
found no significant indication of dose-dependent nicotine effects. Similar to the 
aforementioned studies, this may be because individuals in this study did not have adequate 
experience using ECs, which may have limited the ability of the ECs to cause significant 
behavioral effects.  Dawkins and colleagues (2016) examined effects of two liquid nicotine 
concentrations (6 and 24 mg/ml) among experienced EC users who were allowed to puff ad 
libitum for 60 minutes.  Results indicated that participants engaged in some compensatory 
puffing, such that more puffs – with greater duration – were taken in the 6 mg/ml compared 
to 24 mg/ml condition.  Despite some compensatory puffing, significantly greater plasma 
nicotine concentrations were observed in the 24 mg/ml condition, but interestingly there 
were no significant differences between conditions on alleviation of self-reported nicotine 
withdrawal symptoms or other subjective effects.  
Although research on the topic of how nicotine in EC liquids affects abuse liability 
is still scant, results of these few studies demonstrate that ECs are capable of delivering 
nicotine comparable to CCs, and that greater liquid nicotine concentrations engender 
greater plasma nicotine concentrations in the conditions of the previous studies.  This 
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suggests that ECs could have a high liability for abuse based on their delivery of nicotine 
alone, though it is unclear whether it would rival that of CCs.  Interestingly, none of the 
studies examining multiple nicotine concentrations noted significant differences in 
behavioral effects as a function of nicotine concentration.  It could be speculated that this is 
because users compensate for differences in liquid nicotine concentration by modulating 
their puffing behavior.  But, even when significant differences in plasma nicotine 
concentrations as a function of liquid nicotine concentration were observed (e.g. Dawkins 
et al., 2016), behavioral effects did not differ correspondingly.  As such, these data might 
suggest that liquid nicotine concentration itself is not the sole determinant of abuse 
liability.  With this limited amount of data, however, it is difficult to make definitive 
statements about the role of nicotine in EC liquids.  As such, future research should 
continue to examine the effects of liquid nicotine concentrations on EC abuse liability in 
carefully controlled studies.    
1.3 The Influence of Device Parameters 
Electronic cigarettes can have a myriad of parameters that are adjustable by the 
user and research has begun to delineate the ways in which these parameters affect 
nicotine delivery and the EC using experience.  Shihadeh and Eissenberg (2015) outline 
parameters (e.g. heating element configuration, power levels, liquid tank design) that 
likely play a role in the “dose and rate” at which ECs can deliver nicotine to the user, 
which suggests these parameters could also play a role in ECs’ liability for abuse.  For 
example, parameters associated with the power provided to the heating element (typically 
identified by the arithmetically related variables: !"##"$% = '()*+,-./-010*+23-) likely alter
nicotine delivery to the user.  Research by Gillman and colleagues (2016) has 
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demonstrated that when using machine puffing conditions, there is a systematic increase 
in aerosol yield when power (wattage) is increased, which has also been replicated in 
another study (Talih et al., 2014).  This indicates that power is likely a significant factor 
in the ability of ECs to deliver nicotine to the user.  Unfortunately, no laboratory studies 
have directly tested this possibility.   
There has been much concern about the composition of EC aerosols as a function 
of power levels.  Kosmider and colleagues (2014) tested the effect of differing power 
levels on presence of carcinogenic aldehydes (e.g. formaldehyde or acetaldehyde) in EC 
aerosols and found a significant positive correlation between power and aldehyde 
production.  Subsequent studies replicated this effect (Geiss et al., 2016; Jensen et al., 
2015), leading to the question of whether ECs should be considered a harm-reduction tool 
for CC smoking.  In response to this growing concern, Farsalinos and colleagues (2015) 
allowed experienced EC users to administer puffs from an EC at varying power levels 
and examined subjective effects, while simultaneously measuring aldehyde production in 
the same ECs at corresponding power levels.  Results of this study showed that EC users 
would report a “dry-puff” condition (determined by reports of “bad-taste”) at power 
levels causing high levels of aldehyde production.  Based on these findings, Farsalinos 
and colleagues (2015) argue that EC users naturally avoid the aversive “dry-puff” 
condition and, as such, “exposure to formaldehyde from ECs is minimal to non-existent.”  
Another important EC parameter is the configuration of the heating element.  
Research has demonstrated that, while power levels play a role in nicotine and aldehyde 
production, the configuration of the heating element also affects aerosol composition.  
For example, Gillman and colleagues (2016) tested several different heating elements set 
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to the same power levels and found a wide range of aldehyde concentrations and overall 
particulate yields in EC aerosols.  Another example is use of ‘direct-dripping,’ a method 
whereby liquid is placed directly on wicking material by the user, rather than relying on 
wicking action from a liquid tank on the EC.  Talih and colleagues (2016a) found that 
aldehyde emissions from ‘direct-dripping’ greatly exceeded those from other ECs and 
even CCs, suggesting greater health risk using this method compared to tank type ECs.  
Mechanistically, heating element configuration can affect aerosol production by altering 
temperatures where liquid meets the heating element.  Talih and colleagues (2017) 
explain that heating elements can utilize single or multiple coils, with greater number of 
coils distributing power over a larger total surface area, potentially reducing temperatures 
at the point of aerosolization.  Unfortunately, research has not yet addressed the effects of 
heating element design on ECs when administered by humans.  It could be speculated, 
however, that since amount of aldehyde emissions have been associated with aversive 
subjective effects (e.g. ‘dry-puff,’ Farsalinos et al., 2015), and heating coil configuration 
has been associated with aldehyde emissions, there could be a relationship between 
heating coil configuration and subjective effects.  Future research is, however, necessary 
to test this hypothesis.  
1.4 The Influence of non-nicotine ingredients 
The predominance of research on EC liquid ingredients has focused on nicotine.  
Yet, EC liquids typically contain at least several ingredients, including a substance acting 
as a solvent or ‘carrier,’ which functions to suspending nicotine and make it viable for 
aerosolization.  Two ingredient typically that act as a carrier substance and comprise the 
majority (e.g. 88-96% by weight, NJOY, 2013) of virtually all EC liquids, either alone or 
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in combination, are propylene glycol (PG) and vegetable glycerin (VG).  In addition to 
PG and VG, inclusion of some amount of water, ethanol, and ingredients for the purpose 
of flavoring are commonly found in EC liquids (Etter and Bugey, 2017).  In the United 
States, there are no EC specific ingredient requirements, and no requirement to label 
liquid contents.  Though some manufacturers will voluntarily display listings of some 
ingredients (e.g. PG and VG ratio [but not total volume], and nicotine concentration), 
comprehensive ingredient labels are virtually non-existent.  Food and Drug 
Administration regulation currently being phased in, however, will require all 
manufacturers to disclose EC ingredients.  Though, it is unclear if and when this 
information will be publicly available.  This lack of standardized labelling, amid an 
enormous variety of different liquids being manufactured (e.g. an estimated 7,764 in 
2014 [Zhu et al., 2014]), has made examination of non-nicotine liquid ingredients 
challenging for two reasons: 1) in order to know what ingredients are in EC liquids 
chemical analyses must first be conducted, and 2) even when ingredients are identified 
for experimental examination it is not known how common the ingredients are in other 
liquids (i.e. how generalizable the results will be).   
Despite challenges with identifying specific chemicals added to EC liquids for 
flavoring, a few laboratory studies have examined the role of flavor as a whole in ECs.  
For example, Audrain-Mcgovern and colleagues (2016) compared non-flavored and 
flavored EC liquids and showed that flavored liquids had significantly greater reinforcing 
effects.  St. Helen and colleagues (2017) examined the effects of three different types of 
flavors among experienced EC users and found differences in subjective liking and 
plasma nicotine concentrations between flavors.  Results of these studies demonstrate that 
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the addition of ingredients for flavoring can significantly increase EC liability for abuse 
by altering reinforcing effects, which may be associated with nicotine delivery.  In the 
future manufacturers will hopefully be required to list ingredients in EC liquids, allowing 
researchers to examine the effects of specific flavoring additives so that a more robust 
and generalizable body of knowledge can be formed on this topic.  
Since PG and VG are requisite components of EC liquids that comprise the bulk 
of liquid volume, and manufacturers often voluntarily include the relative ratio of PG and 
VG in liquids, these ingredients are a good candidate for research on non-nicotine 
ingredients in EC liquids.  Laboratory analysis of aerosol production based on PG/VG 
ratio indicates that liquids with greater VG content produce greater light scattering 
coefficients (i.e. visibility of the aerosol) and that PG and VG play a role in nicotine yield 
of aerosols (Baassiri et al., 2017).  Only one study, however, has examined the effects of 
PG and VG on plasma nicotine concentrations in humans and found that formulations 
containing some amount of PG led to greater plasma nicotine concentrations than 
formulations with VG alone (Yan and D’Ruiz, 2015).  This study, however, did not 
examine multiple formulations across the spectrum of PG/VG ratios (e.g. 100/0% to 
0/100% PG/VG), so it cannot be determined what the effects of PG alone are, or whether 
there is a clear dose-response relationship between PG/VG ratios and plasma nicotine 
concentrations.  In addition to laboratory research, a survey of EC users suggests that PG 
is more closely associated with ‘throat hit’ (a term used to describe the sensation of EC 
aerosols on the throat) than VG (Etter, 2016a).  There has not, however, been any 
research to investigate this possibility in a laboratory setting. 
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Since PG and VG are always present in EC liquids, and since the existing 
literature has not yet explored differences in subjective or reinforcing effects of PG and 
VG in EC liquids, this dissertation focused on examining these topics using a survey 
(Chapter 2) and laboratory study (Chapter 3) to determine if these ingredients may affect 
the abuse liability of ECs.  As delineated in the prior sections (‘the influence of nicotine’ 
and ‘the influence of device parameters’), there are several variables that can affect the 
EC using experience, which should be accounted for when studying these devices.  As 
such, prior to conducting the laboratory study, the survey study was used to collect 
information on EC variables typically utilized.  Based on results of this survey study, 
settings most commonly utilized (e.g. wattage and nicotine concentration) were selected 
for EC administration in the following laboratory study.  The survey study was also used 
to assess associations EC users made with PG and VG and several subjective EC effects.  
These results then served as the basis for hypotheses about the subjective and reinforcing 
(i.e., stimulus effects) effects of PG and VG in the following laboratory study.  
 14 
CHAPTER TWO: ELECTRONIC CIGARETTE LIQUID AND DEVICE 
PARAMETERS AND AEROSOL CHARACTERISTICS: A SURVEY OF 
REGULAR USERS 
2.1 Introduction 
Electronic nicotine delivery systems, and specifically ‘electronic cigarettes’ 
(ECs), represent a varied group of devices with user adjustable parameters, including 
heating element variables (such as heater coil configurations and power settings), and 
concentrations of nicotine, a variety of flavorants, and other ingredients in liquids.  Early 
ECs (i.e. ‘first-generation’ ECs) were relatively simple devices that restricted the user 
from altering power levels and heater coil configurations, and typically limited liquids to 
only those sold for a specific device.  ECs evolved from these simpler first-generation 
devices to more complex 2nd and 3rd generation devices.  Key changes include heating 
element control by specifying wattage, voltage, or temperature, adjustable heater coil 
configurations (e.g. number, diameter, length, and materials of coils), and refillable tanks 
that allow the user to control liquid composition.  Because ECs have many variables, it is 
necessary to understand how regular EC users utilize their devices and their parameters to 
construct relevant regulatory policy or maximize efficacy of ECs for smoking cessation.   
One key function of ECs is to deliver nicotine, which is influenced by user-
adjustable parameters.  Previous laboratory research has demonstrated that concentration 
of nicotine in EC liquids can have a significant impact on the EC-using experience and 
the composition of the aerosols they produce.  Expectedly, increases in liquid nicotine 
concentration have been shown to increase concentration of nicotine in EC aerosols 
(Talih et al., 2014) and plasma nicotine levels following EC use, with plasma nicotine 
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levels following high nicotine concentrations (i.e. 3.6% nicotine) exceeding levels 
typically achieved from conventional tobacco cigarettes (CCs) (Ramoa et al., 2016).  The 
nicotine concentration in EC liquids has also been demonstrated to have a negative 
relationship with puff topography, such that EC users will take shorter duration puffs 
from ECs containing higher nicotine concentrations compared to lower concentrations 
(Lopez et al., 2016).  Lastly, previous research has shown that liquids with greater 
proportions of propylene glycol (PG), relative to vegetable glycerin (VG), increases 
nicotine concentration in EC aerosols, which may suggest that PG/VG concentrations 
could alter plasma nicotine concentrations following EC use (Talih et al., 2016b). 
It has also been suggested that EC device parameters affect the level of nicotine 
emitted by ECs.  Shihadeh and Eissenberg (2015) provide a framework for understanding 
the level of nicotine emitted by ECs, emphasizing that many different EC variables 
impact nicotine emission.  Variables in this framework include: liquid container design 
(e.g. cartomizer, tank, drip tip, disposable), heating element parameters (electrical 
resistance, voltage, and surface area of the heating coil), liquid variables (nicotine 
concentration, solvent composition, flavoring, and other additives), and usage behaviors 
(puff duration, inter-puff interval, and number of puffs).  Since these variables likely 
affect nicotine delivery, they also likely affect the abuse liability of ECs.  Additionally, 
these variables can influence the potential harm of ECs.  For example, voltage level 
(directly associated with wattage when coil resistance is held constant), is associated with 
emissions of carcinogens from ECs (Kosmider et al., 2014).  Other research has 
demonstrated that constituents in EC liquids – namely PG and VG – can degrade into 
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carcinogens when used in an EC.  Yet, whether regular EC users typically use ECs in a 
manner that would lead to high levels of carcinogen emission is not well studied.  
It is important to know what factors motivate the initiation and continued use of 
ECs in order to more completely understand their abuse liability and efficacy as potential 
smoking cessation tools.  Farsalinos and colleagues (2013) reported that the majority of 
EC users in their sample use multiple different flavors within a day, and that ECs would 
be ‘less enjoyable’ if flavor availability were limited.  Therefore, taste might drive both 
the initiation and continuation of EC use.  It is unclear from these data, however, what the 
relative contribution of taste is compared to other possible motivations for initiation and 
continuation of EC use.  Users of ECs have also identified “throat hit” as an important 
stimulus characteristic, with reports suggesting that liquid and device parameters (e.g. use 
of higher liquid nicotine concentrations) may be associated with this effect (Etter, 2016a), 
though whether device power (i.e. wattage) is associated with throat hit is not yet known.  
In August 2016, a Food and Drug Administration (FDA) rule came into effect that 
placed ECs under FDA regulation.  Now that there is a regulatory mechanism for ECs it 
is important to study behaviors of regular EC users.  Behaviors of regular EC users may, 
for example, highlight usage patterns that put individuals at undue health risk, which 
would provide an important regulatory target.  Knowing common EC settings and usage 
patterns will also inform future research, such that studies can utilize the most common 
EC user settings to determine if these settings confer significant health risks to the user.  
The extant literature is lacking estimates from a broad sample of regular EC users on key 
variables that likely influence the reinforcing effects of ECs, their potential harms, and 
motivations for initiation and continued use of ECs.  This poses several problems: 1) it is 
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difficult to conduct generalizable research on ECs without knowing what adjustable 
parameter settings are commonly used, 2) it is difficult to assess health risks associated 
with ECs without knowing whether settings that could cause harmful effects are 
commonly used, and 3) it is difficult to employ meaningful regulation without first 
understanding how ECs are being used.  To address this gap in the extant literature, a 
survey of regular nicotine-dispensing EC users in the United States was conducted.  The 
primary goal of the survey was to determine how adjustable parameters are typically 
used, the factors that motivate EC liquid selection, and the factors that influence initiation 
and continuation of EC use.  Also examined was the association between nicotine 
dependence and (1) frequency of EC use, (2) adjustable settings, and (3) liquid 
preferences.  Results of this survey will support the translation of laboratory research 
findings to the natural ecology, and to inform EC-related public health policy efforts.  
2.2 Methods 
2.2.1 Participants 
A non-EC internet marketplace (Amazon’s Mechanical Turk [mTurk]) was used to 
recruit study participants.  A listing on the site invited EC users to complete the survey 
during the spring of 2016.  Participants were first asked 10 screening questions to verify EC 
use and establish eligibility.  To complete the full survey, participants were required to: 
report daily use of an EC – with liquids containing nicotine – throughout the past month, 
use ECs as their primary means of administering nicotine, have a 95% or higher approval 
rating on previously completed mTurk tasks, and be over 18 years of age.  
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2.2.2 Overall Procedure 
Participants were required to complete all questions applicable to them, and were 
not shown questions that did not apply to them (e.g. if a participant indicated not currently 
using tobacco, they were not presented questions regarding tobacco use).  To minimize 
duplicate entries, the survey could be completed on a specific computer only once.  This 
study was approved by the University of Kentucky Institutional Review Board.  
2.2.3 Measures 
The survey was comprised of several sub-sections: a nicotine dependence 
questionnaire (the Penn State [Electronic] Cigarette Dependence Index), tobacco and 
electronic cigarette usage history, device preferences, and liquid preferences.  
Penn State [Electronic] Cigarette Dependence Index (PSCDI). This scale contains 
10 questions regarding use of electronic and tobacco cigarettes and behaviors associated 
with nicotine dependence (Foulds et al., 2015).  Scores range from 0-19, with higher scores 
indicating greater dependence on electronic and tobacco cigarettes.  
Tobacco and Electronic Cigarette Usage History: This experimenter-designed 
section consisted of seven items assessing quantity and frequency of EC usage, and reasons 
for initial and continued use.  Questions included: ‘do you own an electronic cigarette 
[yes/no],’ ‘were you a regular tobacco user prior to using an electronic cigarette,’ ‘are you 
currently trying to quit using tobacco products,’ ‘are you currently trying to quit using 
tobacco products by using electronic cigarettes,’ ‘how long ago did you begin using an 
electronic cigarette regularly,’ ‘why did you first begin using an electronic cigarette,’ and 
‘why do you continue to use an electronic cigarette?’   For the last two questions, 
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participants were given a list of possible options to choose from, including an option to 
write-in an unlisted reason.  
Device Preferences: This experimenter-designed section was comprised of six 
items assessing the type of EC participants typically use and its parameter settings.  
Questions included: ‘what is the brand of your preferred electronic cigarette tank,’ ‘can you 
change the voltage of the electronic cigarette that you typically use,’ ‘what voltage do you 
typically use,’ ‘what is the typical resistance (in ohms) of the coils,’ ‘how many watts do 
you typically use,’ ‘is the electronic cigarette you typically use rechargeable?’  In order to 
facilitate accurate responses an annotated picture of a common EC coil was shown to the 
participant describing how to determine coil resistance.  
Liquid Preferences: This experimenter-designed section was comprised of eight 
items assessing EC liquid preference.  Participants were asked: what types of liquid they 
purchase (‘pre-filled disposable tanks or cartridges,’ ‘pre-mixed ready-to-use liquids for 
refillable tanks,’ ‘mix own liquids using basic ingredients’), how much liquid they use per 
week (in ml or number of cartridges).  Participants were also asked if they ‘pay attention to 
the amount of nicotine’ in the liquids they use and, if so, what the ‘nicotine concentration 
of the liquids’ they ‘typically use in mg/ml.’  Participants were asked to rate ‘what effects 
of electronic cigarette liquid are most important to you,’ and ‘when purchasing or making 
electronic cigarette liquids what factors are most important to you,’ with possible answers 
based on previous research indicating common factors EC users consider when selecting 
liquids (Farsalinos et al., 2014a).  Ratings of these factors were entered using a 100-point 
scale anchored with ‘least important’ and ‘most important’ on either end.  Participants were 
also asked if they ‘pay attention to the amount of propylene glycol (PG) and vegetable 
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glycerin (VG) in EC liquids’ and, if so, the percentage of PG and VG in the liquids they 
typically use, and whether liquids with more PG or VG are most closely associated with 
several effects.  Ratings were entered on a 100-point scale anchored on one end with ‘PG,’ 
and ‘VG’ on the other.   
2.2.4 Data Analysis 
Descriptive statistics were used to examine distributions of demographic variables, 
device parameter preferences, and liquid preferences.  Milligrams of nicotine used per 
week was estimated based on milliliters of liquid used per week and nicotine concentration 
typically used.  To examine possible relationships of nicotine dependence with tobacco 
usage behaviors, liquid and device preferences, and subjective effects, correlational 
analyses were conducted between total score on the PSCDI and items from the tobacco and 
EC usage history, device preferences, and liquid preferences questionnaires.  Since the 
PSCDI includes an item directly related to quantity of EC use (i.e. “How many cigarettes 
and times per day do you usually smoke or use your electronic cigarette?”), total scores 
were recalculated omitting this item for correlational analysis involving other direct 
measures of EC use (i.e. number of milliliters, disposable cartridges, or milligrams of 
nicotine used per week).  Based on previous data indicating that nicotine concentration is 
associated with “throat hit,” (Etter, 2016a) ratings of “throat hit” and parameters (power, 
power multiplied by nicotine concentration, and milligrams of nicotine used per week) 
impacting nicotine exposure were also examined.  To examine whether subjective EC 
effects were more closely associated with PG or VG, differences from the midpoint were 
evaluated using t-tests.  The alpha value for all analyses was set at ≤ .05. 
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2.3 Results 
A total of 1,586 participants answered screening questions, and the 522 individuals 
that met inclusion criteria completed the entire survey.  Participants were comprised of 290 
(55.7%) females with an average age of 33.0 (SD=10.2).  Descriptive statistics are shown in 
tabular form for usage behaviors and settings (Table 2.1) and liquid variable preferences 
(Table 2.2). 
Fifty-nine percent of individuals endorsed currently using at least one other tobacco 
product in addition to ECs.  Endorsement of current use of another tobacco product (i.e. 
cigarettes, snus or chewing tobacco, cigars, or hookah) was associated with significantly 
higher scores on the PSCDI (i.e. level of nicotine dependence, Table 2.1).  Not having used 
other tobacco products besides ECs was negatively associated with PSCDI scores (Table 
2.1), with never other tobacco product users having lower PSCDI scores (m=6.1, SD=4.4) 
compared to past other tobacco product users (m=9.81, SD=4.0) and current other tobacco 
product users (m=10.3, SD=3.58), and no significant differences in length of EC use were 
found between these groups.  Two parameter setting preferences were significantly 
associated with PSCDI scores, heater coil resistance (in ohms) and ability to change voltage 
on the device (Table 2.1).  Among the 197 individuals who knew the wattage they typically 
used and who provided ml’s of liquid typically used per week, there was a positive 
correlation between wattage and ml’s used (r=.20, p=.005).   
When asked to rate “what effects of liquids are most important to you” from ‘most 
Important’ (100) to ‘least important’ (0), participants rated ‘good taste’ (m=87.3, SD=15.7), 
‘does not cause sore throat’ (m=77.3, SD=23.4), and ‘does not cause headache’ (m=76.7, 
SD=26.3) as the three most important factors (Figure 2.1).  When asked ‘when purchasing 
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or making liquids what factors are most important to you’ participants again indicated that 
the most important factor is ‘good taste’ (m=88.0, SD=13.6), followed by ‘availability’ of 
the liquids (m=73.8, SD=23.0), and ‘decreased health risks, avoid certain ingredients’ 
(m=73.4, SD=27.0), and ‘low price’ (m=72.6, SD=24.3).  ‘Throat hit’ received a more 
moderate rating of importance (m=65.8, SD=28.0).  A significant correlation was found 
between ratings of the importance of ‘throat hit’ and nicotine concentration (r=.19, p<.001) 
and milligrams of nicotine consumed per week (r=.14, p<.019), but not power or nicotine 
concentration multiplied by power.   
The majority of users (74.2%) indicated using liquids purchased for ECs with 
refillable containers (further separable as 'pre-mixed' liquids [64.8%] or liquids mixed by 
the end-user from basic ingredients [9.4%]), and while no differences in nicotine 
dependence scores were observed as a function of type of liquid purchased, amount of 
liquid used was positively correlated with PSCDI scores (Table 2.2).  Seventy percent of 
individuals reported paying attention to the nicotine concentration of the liquids they 
typically used, and nicotine concentration was positively correlated with PSCDI scores 
(Table 2.2).  Among the 188 (36.0%) individuals who indicated wattage and nicotine 
concentration typically used, there was a significant negative correlation between these two 
variables (r(188)=-.23, p=.002).  Among 285 (54.6%) participants who reported paying 
attention to nicotine concentration and milliliters of liquids used for refillable devices, 
milligrams of nicotine used per week was positively correlated with PSCDI scores (Table 
2.2).  Lastly, 239 (45.8%) individuals reported paying attention to the amounts of PG and 
VG in the liquids they typically use, and this was not significantly correlated with PSCDI 
scores. 
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When asked to rate which effects were more closely associated with PG or VG, 
participants indicated that PG was more closely associated with dry mouth (t[237]=6.232, 
p<.001), sore throat (t[237]=7.432, p<.001), headache (t[237]=6.909, p<.001), and 
dizziness (t[237]=4.417, p<.001).  VG was significantly associated with large cloud 
(t[237]=6.794, p<.001), good smell (t[237]=8.102, p<.001), and good taste (t[237]=6.607, 
p<.001).  Throat hit was not significantly associated with PG or VG.  
2.4 Discussion 
This study addresses critical gaps in our understanding of EC use by providing 
detailed information on EC usage behaviors, device parameter settings, and liquid 
variables among regular (i.e. daily) EC users.  EC users utilize a wide variety of devices, 
power levels (i.e. watts, volts, ohms), and nicotine concentrations.  These data suggest 
that no predominant combinations of user-adjustable products have emerged from the 
broad range of commercial options. Consistent with previous findings (Farsalinos et al., 
2014a), taste was identified as the most important variable when using ECs or purchasing 
liquids.  Desirable effects were associated with the ingredient VG, and undesirable effects 
with PG, suggesting that these ingredients might influence the reinforcing effects of ECs.  
One of the primary goals of this survey was to determine the adjustable parameter 
settings typically used.  Key among these settings is wattage, a measure of power output 
that is arithmetically related to voltage and resistance by the equation: !"##"$% =
4()*+,-.5-010*+23-.  The median wattage reported is approximately 10 watts, but many individuals
reported setting their ECs to power levels of up to 10 times greater (100 watts), indicating 
that a wide range of power levels are utilized.  Many individuals indicated not knowing 
the wattage of their device (57.7%), which is comparable to previous research where 
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most participants reported not knowing the voltage (51.5%) or resistance (63.6%) of their 
devices (Rudy et al., 2017).  This indicates a need for more reliable, and potentially more 
objective, approaches to determining common EC parameter settings.  It should be noted 
that the wattage scale was limited to 0-100 watts, as at the time of this survey few, if any, 
popular EC manufacturers offered devices capable of delivering more than 100 watts.  
For example, in late 2015 the most commonly used brand of device by participants in this 
survey (Kangertech, used by 15.5% of participants) offered power supplies rated to a 
maximum of 60 watts (Kangertech, 2017a).  More recently, however, this brand began 
offering products capable of delivering up to 200 watts (Kangertech, 2017b).  A recent 
study by Wagener and colleagues (2017) also measured wattage ratings of a small sample 
of third-generation ECs and found power levels exceeding 100 watts.  Thus, 100 watts 
may have been too low of a threshold, and greater power levels may have been used at 
the time of this survey, or since the completion of this survey.  Despite this potential 
limitation, data on power levels has a right skewed distribution with a mean of 28.3 watts 
and SD of 24.2 (Figure 2.3), suggesting that most users utilized power levels below 100 
watts.  Importantly, future research should closely monitor changes in power settings 
since previous research has indicated a positive relationship between power levels and 
amount of potentially harmful chemicals in EC aerosols (Jensen et al., 2015; Kosmider et 
al., 2014).  
Overall scores on the PSCDI in the current study were slightly higher than scores 
among exclusive EC users in a previous study (m=8.1) (Foulds et al., 2015).  Participants 
in Foulds and colleagues (2015) were exclusive EC users with a history of CC use.  
Comparing ex-CC smokers from the current study, average PSCDI scores were still 
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slightly higher (i.e. m=9.8, SD=4.0).  It could be speculated that this is because use of 
newer ECs (i.e. those introduced following Foulds et al. [2015]) is associated with higher 
levels of nicotine dependence, particularly if ECs are used in a manner that causes plasma 
nicotine concentrations to exceed those typically seen following CC use (e.g. Ramoa et 
al., 2016).  This is a concern shared by Cobb and colleagues (2015), who speculate that 
sole use of ECs may engender greater nicotine dependence than use of CCs.  Yet, 
participants from the current study who reported no previous use of non-EC tobacco 
products reported significantly lower PSCDI scores compared to current or ex-CC 
smokers, suggesting that sole use of ECs with no CC history does not engender greater 
nicotine dependence.  
Interestingly, wattage was not significantly associated with level of nicotine 
dependence (Table 2.1), but there were associations with ability to change voltage on the 
device and resistance of the heater coil.  This may be related to type of device, as 
typically only 2nd or 3rd generation devices allow the user to adjust voltage and coil 
resistance, while 1st generation do not.  The positive correlation between heater coil 
resistance and nicotine dependence may seem counterintuitive because lowering heater 
coil resistance while holding voltage constant would produce higher power levels. 
Additional research is required to further explore the relationships between use of a 
device with variable voltage and greater nicotine dependence, and between heater coil 
resistance and nicotine dependence. 
The distribution of nicotine concentrations (Figure 2.3) indicates that the most 
common concentration is 3 milligrams/milliliter (.3%) with peaks at commonly sold 
nicotine concentrations (multiples of 3).  Mean nicotine concentration was 9.1 (SD=7.2), 
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which is comparable to an estimate of 9.5 (SD=7.3) by Rudy and colleagues (2017).  
While there was not a significant correlation between wattage and nicotine dependence, 
there was a significant negative correlation between wattage and nicotine concentration, 
indicating that while individuals use a variety of power levels, nicotine concentration is 
decreased when power levels are increased.  It should be noted, however, that more 
powerful devices may alter the rate of nicotine delivery (Farsalinos et al., 2014b).  
Amount of liquid used per week was positively associated with power levels.  As such, it 
could be hypothesized that power level selections may impact weekly nicotine intake.  
There were significant correlations between nicotine dependence and (1) the amount of 
liquid typically used per week (as measured by disposable cartridges or milliliters of 
liquid), (2) typical nicotine concentration, and (3) quantity of nicotine used per week, 
with quantity of nicotine use per week serving as a better predictor of nicotine 
dependence than milliliters of liquid used per week (Table 2.2).  These findings suggest 
that weekly intake of nicotine is a potentially useful measure for future EC research. 
 When asked "what effects of e-cig liquid are most important to you” or “when 
purchasing or making electronic cigarette liquids what factors are most important to you” 
respondents indicated that taste was most important.  This is consistent with previous 
research indicating taste as the most important motive for EC use (Temple et al., 2017) 
and that regular EC users modify their devices primarily to improve taste (Etter, 2016b).  
Though “throat hit” was not ranked highly in importance among other stimulus 
characteristics in this study, consistent with Etter (2016a), it was positively correlated 
with nicotine concentration and, additionally, amount of nicotine consumed per week.  
This suggests that individuals who value throat hit may modulate nicotine concentration 
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and overall consumption to optimize this characteristic.  When participants were asked 
which effects were most closely associated with PG and VG, PG was significantly related 
to potentially undesirable effects (dry mouth, sore throat, headache, and dizziness), while 
VG was associated with potentially desirable effects (large cloud, good smell, good 
taste).  These results suggest that liquids with greater VG concentrations may have 
greater reinforcing effects, particularly since taste was indicated as the most important 
factor in liquid preference.  It should be noted, however, that although participants 
indicated VG being more closely associated with desirable effects, on average 
participants used liquids containing approximately 1:2 ratios of PG and VG, suggesting 
that choice of PG/VG concentrations may not be driven exclusively by associated 
stimulus characteristics.  One other possibility is that PG has been shown to increase 
nicotine yield in EC aerosols (Baassiri et al., 2017), which could play a role in the 
inclusion of PG in EC liquids.  
Several potential limitations of this survey should be noted.  First, participants in 
this study may not be representative of all regular EC users in the United States.  For 
example, participants were required to use ECs containing nicotine to participate in this 
survey and therefore these results may not generalize to use of non-nicotine containing 
ECs.  It could be speculated that individuals using ECs that do not contain nicotine may 
place greater importance on different subjective effects, and perhaps have lower nicotine 
dependence scores.  These results may also not generalize to an adolescent population.   
Adolescents have had less opportunity to use other tobacco products and therefore may 
be more likely to initiate nicotine use with ECs.  For example, a recent survey indicated 
that 9.9% of high school seniors used only an EC in the past month, while only 6.0% 
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reported using conventional cigarettes (McCabe et al., 2017), suggesting that exclusive 
EC use may be more frequent among high among adolescents than was observed in the 
current study.  Second, not all EC users paid attention to certain device parameters (e.g. 
wattage, voltage, resistance) or liquid (e.g. nicotine concentration, PG/VG ratios) 
variables.  As such, it is possible there were systematic differences between users who 
did and did not pay attention to these variables (e.g. individuals using early generation 
ECs may have been less likely to pay attention to device characteristics that are not 
modifiable or displayed on the device itself).  Third, although careful steps were taken to 
increase reliability of reports on device and liquid characteristics (e.g. first confirming 
that users ‘pay attention’ to the variable in question before asking them to report the 
value, showing a picture of where heater coil resistance values are typically found on the 
device), it is still possible that users were inaccurate on reports of adjustable parameter 
settings.  Lastly, although detailed information on EC parameters was collected, 
additional variables (e.g. heater coil configuration or heater coil materials) should be 
considered in future studies.   
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EC= electronic cigarette.  *Based on responses only from individuals indicating they knew what the wattage, voltage, or resistance 
they typically used was (N of these individuals indicated after each setting). 
Table 2.1 Usage Behaviors and Settings Relationship with 
PSCDI, r (p) 
  Currently using ECs and other tobacco products, N (%) 
      Portion of other tobacco product users trying to quit, N (%) 
  Former regular user of other tobacco products, N (%) 
  Began regular other tobacco product use after ECs, N (%) 
  Never used tobacco products besides ECs, N (%) 
  Types of non-EC tobacco Used 
  Tobacco cigarettes, N (%) 
  Snus or chewing tobacco, N (%) 
  Cigars, N (%) 
  Hookah, N (%) 
  Months of EC use, mean (SD) 
  Penn State [Electronic] Cigarette Dependence Index Score, mean (SD) 
  Can you change the voltage on the EC you typically use, N (%) 
  Typical power settings* 
  Wattage (N = 221), mean (SD) 
  Resistance in Ohms (N = 255), mean (SD) 
  Voltage (N = 371), mean (SD)  
308 (59.1) 
261 (84.7) 
180 (34.4) 
7 (1.3) 
34 (6.5) 
285 (54.6) 
34 (6.5) 
52 (10.0) 
61 (11.7) 
  13.9 (7.9) 
10.0 (4.0) 
315 (60.4) 
28.3 (24.2) 
1.1 (0.8) 
2.9 (1.8 
.070 (.111) 
.022 (.616) 
-.678 (<.001) 
.003 (.952) 
-.203 (<.001) 
.710 (<.001) 
.172 (<.001) 
.190 (<.001) 
.266 (<.001) 
-.007 (.876) 
-- 
.257 (<.001) 
.031 (.555) 
.096 (.035) 
.041 (.262) 
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PSCDI= Penn State [Electronic] Cigarette Dependence Index.  *Represents only individuals who reported paying attention to the 
nicotine concentration they typically used.  †Calculated by multiplying reported mg/ml liquid nicotine concentration by milliliters of 
liquids typically used per week and represents only users who do not use disposable containers and who pay attention to the amount of 
nicotine in their liquids.  †Amounts include only individuals who indicated that they “pay attention” to the amount of propylene glycol 
and vegetable glycerin in liquids. 
Table 2.2 Electronic Cigarette Liquid Variables Association with 
PSCDI, Statistic (p) 
Type of liquid/container typically used      
 Disposable container, N (%)  
 Pre-mixed for refillable devices, N (%)  
 Liquid mixed by user from basic ingredients, N (%) 
Amount of liquid typically used per week 
 Number of disposable cartridges (25.7% of users), mean (SD) 
     Milliliters of liquid for refillable devices (74.2% of users), mean (SD) 
Typical nicotine concentration used (mg/ml) (N=366),* mean (SD)  
Milligrams of nicotine used per week (N=285),† mean (SD) 
Typical percentage of propylene glycol and vegetable glycerin (N=239)†      
 Vegetable Glycerin, mean (SD) 
 Propylene Glycol, mean (SD) 
131 (25.7) 
330 (64.8) 
48 (9.4) 
3.7 (2.9) 
22.9 (26.0) 
9.1 (7.2) 
192.5 (254.0) 
63.3 (20.6) 
36.7 (20.6) 
F = .871 (.419) 
-- 
-- 
r = .288 (<.001) 
r = .112 (.029) 
r = .214 (<.001) 
r = .244 (<.001) 
r = -.060 (.388) 
-- 
31  Participants were asked to rate all effects by placing a slider on a scale anchored on the left at 0 (“Least Important”) and on the right at 
100 (“Most Important”).  Columns represent mean values and error bars represent standard error of the mean. 
Figure 2.1 “What effects of liquids are most important to you?” 
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Participants were asked to rate whether these effects were more closely associated with propylene glycol or vegetable glycerin on a 
scale of -50 to +50, respectively, with 0 indicating neither. All effects except ‘Throat Hit’ were significantly different than 0 (ps<.05). 
Figure 2.2 “Are vegetable glycerin or propylene glycol more closely associated with these effects?” 
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Information displayed is only from participants that reported knowing the wattage their device is typically set at (N=221) (left figure), 
or those who pay attention to the nicotine concentration of the liquids they use (N=366) (right figure). 
Figure 2.3 Distributions of wattages and nicotine concentrations 
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CHAPTER THREE: STIMULUS EFFECTS OF PROPYLENE GLYCOL AND 
VEGETABLE GLYCERIN IN ELECTRONIC CIGARETTE LIQUIDS 
3.1 Introduction 
Electronic cigarette (EC) use has been rapidly growing worldwide.  While there is 
ongoing debate about whether ECs serve as harm reduction devices for conventional 
tobacco smokers or present new public health problems, it is important to examine factors 
that affect their abuse liability.  Currently, a major gap in our understanding of ECs is 
how non-nicotine liquid ingredients influence reinforcing and stimulus effects of EC 
aerosols.  
Propylene glycol (PG) and vegetable glycerin (VG) comprise most of EC liquids 
(e.g. 88-96% PG and VG by weight, NJOY, 2013).  Previous research suggests that ratio 
of PG and VG could impact the stimulus characteristics of ECs.  For example, regular EC 
users associate PG or VG with differences in taste and sensations (e.g. ‘throat hit’ and 
‘dizziness’) (Etter, 2016a; Harvanko et al., 2018).  Though these studies suggest PG and 
VG alter stimulus effects of ECs, it is necessary to conduct a carefully controlled double-
blind laboratory study to verify these effects.   
Clarifying the relative effects of PG and VG would lay important ground work for 
future research on ECs.  Regulatory efforts to decrease abuse liability of ECs would 
benefit from information about the influence of PG and VG on stimulus effects.  Efforts 
to improve the efficacy of ECs as harm reduction devices for smoking cessation would 
also benefit from this information.  The current laboratory study was conducted to 
examine the stimulus effects of aerosol as a function of relative concentrations of PG and 
VG.  Based on EC user survey data (Etter, 2016a; Harvanko et al., 2018), it was 
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hypothesized that greater concentrations of VG would engender desirable stimulus effects 
(e.g. good taste, large cloud), while greater concentrations of PG would engender 
undesirable stimulus effects (e.g. sore throat, headache).  
3.2 Methods 
3.2.1 Participants  
Participants were recruited from the local community using online 
advertisements.  Prospective participants made initial contact by phone or internet and 
responded to a brief screening questionnaire.  Participants who would potentially meet 
study criteria were invited into the laboratory for a screening day.  Volunteers reporting 
use of an EC at least 20 of the past 30 days (containing nicotine the majority of the time), 
and no desire to reduce their EC usage, were invited to participate.  Individuals were not 
informed of the specific inclusion/exclusion criteria for participation.  Screening days 
were conducted on an outpatient basis at the laboratory and lasted between 2 and 3 hours 
on one day.  Screening days involved a full discussion of the study protocol, obtaining 
informed consent for the screening procedure, assessment of vital statistics (i.e., heart 
rate, blood pressure, weight and height), pregnancy urine test for female volunteers, urine 
screen for psychoactive drugs that may alter the effects of nicotine, verification of recent 
EC use by urinary cotinine test, and completion of screening materials.  Screening 
materials consisted of drug-use, personality, and medical history questionnaires.  
Participants also provided expired breath samples that were tested for the presence of 
alcohol (BAC) and carbon monoxide (CO; used to estimate recent tobacco use).  Current 
EC use was verified by a timeline follow-back questionnaire (TLFB) (Sobell and Sobell, 
1992).  After participants completed the screening materials, results were evaluated by 
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the study staff and study physician, Catherine Martin, MD; individuals were excluded if 
they reported any condition that would increase risk for study participation, such as 
recent use of psychoactive drugs other than caffeine or alcohol.  If approved, participants 
were invited to schedule the initial practice study day.  Study compensation consisted of 
per diem payments ($50.00), monetary earnings from the Multiple Choice Procedure 
(described below) and a final payment ($250.00) provided upon completing all scheduled 
test days.  Sixteen volunteers provided informed consent, and all completed the study.  
This study was approved by the University of Kentucky’s Institutional Review Board and 
accorded with the Declaration of Helsinki.  
3.2.2 Procedures 
An EC with a refillable tank (Nautilus, Aspire, Shenzhen, China) and adjustable 
power supply (iStick TC100W, Eleaf, Shenzhen, China) set to 10 watts (3.7 volts, 1.4 
ohm heating coil) was used for aerosol administration.  Participants completed one 
practice day and four test days, each approximately 3 h long.  Each day five liquid 
formulations (100/0, 75/25, 50/50, 25/75, 0/100 PG/VG) all containing 12 mg/ml nicotine 
were assessed in a random order that was balanced between test days and participants.  
The initial practice day was used to familiarize participants with study procedures and 
data were collected but not analyzed.   
On each test day (see Table 3.1), an intake assessment comprised of the following 
events that occurred in a fixed order was completed within the first 30 minutes: 
completion of questionnaires asking about amount of tobacco smoking and EC use, hours 
of sleep, and drug use in the past 24 h; a field sobriety test (requiring participants to 
estimate the passage of 30 seconds, balance on one-leg, walk and turn, and touch their 
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pointer finger to their nose) that was used to detect acute drug effects and to serve as a 
reference for a post-day field sobriety test; consumption of a fat- and caffeine-free snack 
in order to standardize nutritional conditions; breath (exhaled carbon monoxide to 
estimate recent combustible tobacco use and blood alcohol concentration) and urine 
(tested to ensure non-pregnant status and for presence of common drugs of abuse) sample 
assays to detect use of drugs that may alter study measures; and collection of baseline 
control measures (i.e. cardiovascular measures, QSU-B, and VAS-SE [each described 
below]).  In order to standardize nicotine levels and EC use prior to completing test day 
measures, participants then administered ten three-second puffs, with 30-second inter-
puff intervals, from an EC containing liquid with 50/50 PG/VG and 12 mg/ml nicotine 
concentration.  These puffs, as well as all subsequent puffs, were administered through a 
volumetric analyzer (SPA-D; Sodim, France) to measure puffing topography.  Following 
these 10 puffs, there was a one-hour deprivation period during which participants waited 
in the laboratory until beginning the first choice procedure.  
Each choice procedure began with completion of the QSU-B and VAS-SE control 
measures (described below), followed by two three-second sample puffs with 30 second 
inter-puff intervals from one of the liquid formulations.  Participants were told to pay 
careful attention to the sample puffs, as they would have an opportunity to choose 
between an amount of money or two more puffs from the same formulation following 
these sample puffs.  Immediately following sampling puff administration heart rate and 
blood pressure measurements were taken and the DSQ, QSU-B, VAS-SE, VAS-PS, and 
MCP (described below) were completed in a fixed-order.  Then, a randomly chosen 
selection from the MCP was honored.  If the randomly chosen selection was for two more 
 38 
puffs, the participant followed computer prompts to administer two more puffs from the 
same formulation.  If the randomly chosen selection was for money, that amount was 
added to the per diem compensation and provided at the end of the test day.   
Five choice procedures occurred during each test day, with each of the five liquid 
formulations tested under double-blind conditions during one choice procedure in an 
order that was balanced between test days and participants. Twenty minutes separated 
successive choice procedures to allow any effects of the sampling puffs (and puffs 
administered following the MCP, if applicable) to diminish and to minimize the 
accumulation of nicotine across the test day.  Following the last choice procedure, the 
participants were required to wait 30 min until being discharged from the laboratory to 
ensure that the opportunity to take puffs of their own EC immediately after leaving the 
laboratory had minimal influence on study outcomes.  Participants were required to 
repeat the field sobriety task to assess for any residual performance effects associated 
with the study procedures prior to receiving daily compensation and discharge. 
3.2.3 Measures 
Control measures 
Cardiovascular Measures  (Dinamap Pro 200, General Electric).  Heart rate and 
blood pressure were recorded using an automated blood pressure monitor.  
Puff Topography (Spa-D; Sodim, France).  Puff topography was recorded with a 
volumetric transducer and measures included total puff volume and duration.   
Questionnaire of Smoking Urges - Brief (QSU-B) (Cox et al., 2001).  This 10-
item questionnaire focuses on nicotine withdrawal and was used to monitor nicotine 
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withdrawal effects on a 100-unit visual analog scale (VAS) before and after formulation 
sampling. 
Visual Analog Scale - Smoking Effects (VAS-SE) (Blank et al., 2008).  This ten-
item measure was used to monitor acute nicotine effects on a 100-unit VAS scale before 
and after formulation sampling. 
Outcome measures 
Duke Sensory Questionnaire (DSQ) (Westman et al., 1996).  This seven-item 
questionnaire asks participants to rate stimulus effects associated with smoking on a 7-
point Likert scale. 
Visual Analog Scale - Post Sampling (VAS-PS).  This 12-item questionnaire 
assesses taste and other stimulus effects associated with the use of ECs using a 100-unit 
VAS scale.  Items included: “feel stimulated,” “like the effects,” “want to use the 
electronic cigarette again,” “enjoy the electronic cigarette,” “crave the electronic 
cigarette,” “get pleasure from the electronic cigarette,” “produce a large vapor cloud,” 
“experience a throat hit,” “feel dry-mouth,” “feel sore-throat,” “enjoy the smell,” and 
“enjoy the taste?”  
Multiple Choice Procedure (MCP) (Griffiths et al., 1993).  The MCP was 
comprised of 21 choices between two more three-second puffs of the sampled liquid 
formulation or an amount of money beginning at $.00 and increasing in increments of 
$.05 until $1.00 was reached.  A randomly selected choice was honored.  If two more 
puffs were selected on this choice, two more puffs from the same formulation were 
administered following control and outcome measures.  If money was selected, that 
amount was added to compensation provided at the end of the test day.  The dependent 
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variable on this measure was the breakpoint at which participants chose money over two 
more puffs.   
3.2.4 Data Analysis 
Mixed models were used to examine differences among liquid formulations.  For 
control measures that were taken immediately before and after puffing bouts (e.g. the 
VAS-SE and QSU-B), change scores were calculated for each formulation.  Since heart 
rate and blood pressure were taken at the beginning of each test day and following each 
puff bout, change scores from baseline for each test day were calculated to account for 
daily fluctuations in resting heart rate and blood pressure.  Control measures were 
included to detect prototypical acute nicotine and withdrawal effects as a function of the 
test formulations and choice procedures.  On measures taken following puffing bouts (i.e. 
DSQ, VAS-PS, and MCP), raw scores were analyzed.  Contrasts for linear and quadratic 
dose-response across the formulations were used to examine main effects.  Analyses were 
conducted using PC-SAS, version 9.3 (SAS Institute Inc., Cary, NC) and alpha was set at 
p ≤ 0.05.  
3.3 Results 
Demographic and clinical variables are reported in Table 3.2.  The majority of 
participants were young (25 years old) male (75%) exclusive EC users (87.5%) with a 
moderate level of nicotine dependence (14.8 on the mFTND).  An overview of all 
statistical test results is shown in Table 3.3.  
Control Measures 
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On average, each puff produced 168.13 (SE = 20.30) ml of aerosol and lasted 4.10 
(SE = .30) seconds in duration.  There were no significant effects of liquid formulation on 
duration or volume of the puffs. 
Heart rate significantly decreased an average of 6.07 (SE=1.90) beats per minute 
from baseline for all of the liquid formulations (ps<.05), this change in heart rate did not 
vary significantly with formulation.  There was a significant change in systolic blood 
pressure (SBP, Figure 3.1) (F[55]=3.67, p=.010) with post-hoc tests indicating a 
quadratic relationship among formulations (F[55]=12.66, p<.001), such that SBP 
decreased significantly more following 100/0 PG/VG (m=-6.55, SE=1.60) and 0/100 
PG/VG (m=-4.47, SE=1.47) compared to 50/50 PG/VG (m=-6.5, SE=1.60). 
Mixed models for QSU-B or VAS-SE items did not indicate significant effects of 
liquid formulation (Table 3.3). 
Outcome Measures 
For DSQ items, there was a significant effect of liquid formulation on “how much 
nicotine do you estimate was in the puffs” (F[60]=3.05, p=.023) (Figure 3.2), “what was 
the strength of the puffs on your tongue” (F[60]=3.98, p=.006), and “what was the 
strength of the puffs in your chest” (F[60]=3.52, p=.012) (Figure 3.3).  Post-hoc tests 
indicated quadratic relationships between liquid formulation and these items, such that 
mixtures of PG/VG were rated more highly than PG or VG alone (e.g. right panel, Figure 
3.4).  The magnitude of effect, however, was small with a maximum difference of .5 units 
between all formulations on this five-point scale. 
For VAS-PS items, significant effects of liquid formulation were indicated on 
“did the e-cig produce a large cloud” (F[60]=2.77, p=.035) and “did you experience a 
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throat hit” (F[60]=3.43, p=.014) (Figure 3.5).  Post-hoc tests indicated a linear 
relationship on large cloud (F[60]=10.59, p=.002) (left panel, Figure 3.4) and a quadratic 
relationship on throat hit (F[60]=7.66, p=.008), such that throat hit was rated slightly 
lower on formulations containing 100% VG (36.4, SE=5.7) or 100% PG (32.4, SE=5.7) 
compared to formulations with 50/50% PG/VG (38.0 SE=5.7). 
No effects of formulation were observed on the MCP.  Notably, monetary value 
of these formulations was low, with the average breakpoint for all formulations being 
$0.04 (SE = .02) (Figure 3.6).     
3.4 Discussion 
This is the first laboratory study of the stimulus effects of aerosols based on 
variations in PG and VG concentration in EC liquids.  Consistent with our hypotheses, 
liquid formulations with more VG were associated with greater visibility of exhalant.  
Also, liquids with equal concentrations of PG and VG mixtures were associated with 
greater strength on the tongue and other common CC sensations, and smaller reductions 
in systolic blood pressure compared to liquids with solely PG or VG, although the 
magnitude of these effects were small.   
Visibility of the exhalant is of interest to many EC users and has been noted as an 
important factor for mimicking the experience of using a conventional cigarette (CC) 
(Barbeau et al., 2013).  Since greater concentrations of VG were associated with this 
effect, this information could be used to tailor ECs for those who place importance on 
greater “cloud” production.  Past research has also shown that EC users associate throat 
hit with smoking cessation efficacy of the EC (Etter, 2016a), as presence of throat hit 
creates a greater resemblance to CC smoking (Barbeau et al., 2013).  Since throat hit and 
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other CC inhalation sensations were associated with PG/VG mixtures (e.g. 50/50 
PG/VG), incorporating both ingredients in EC liquids may be helpful for tailoring ECs to 
individuals desiring an experience more closely resembling that of CCs. 
This study was designed to assess stimulus effects of the EC liquid formulations 
under controlled flavorant, nicotine, and nicotine withdrawal conditions.  Given 
individual differences in flavor preferences, formulations devoid of flavorants were used.  
Plasma nicotine was not measured, but there were no differences indicated between 
formulations on control measures (i.e. VAS-SE, and QSU-B, Table 3.3).  Also, average 
heart rate following puffing did not change as a function of liquid formulation, suggesting 
that nicotine delivery was not significantly different between formulations under these 
conditions.  There was, however, an interesting quadratic relationship between 
formulations and SBP (Figure 3.1).  Yet, interpreting this finding is difficult because 
nicotine delivery is typically associated with changes in heart rate rather than blood 
pressure (e.g. Benowitz et al., 1982).  It should be noted, however, that previous research 
has suggested PG and VG can influence nicotine delivery (Yan and D’Ruiz, 2015; 
Baassiri et al., 2017).  Thus, further research on the effects of these ingredients on plasma 
nicotine concentration is warranted. 
Breakpoints on the MCP were low for each of the liquid formulations, indicating 
a floor effect that limits interpretation of these data.  One possibility for the modest 
monetary value of these formulations was the omission of flavorants.  Reports of ‘good 
taste’ were low following puffing (<15 on a 100-unit scale), and spontaneous reports by 
participants indicated dissatisfaction with the flavor.  Thus, the reinforcing effects of ECs 
appear to be dependent on flavorants. 
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In a recent survey (Harvanko et al., 2018) EC users associated PG with sore 
throat, headache, and dizziness, and VG with good smell, cloud production, and taste.  
There were, however, no significant differences reported on most of these items in the 
present study.  This may suggest that – aside from cloud production – common 
perceptions of PG and VG effects among experienced EC users may not be accurate.  It is 
also possible that conditions in this study may have reduced the likelihood that PG/VG 
effects reported in the survey study could be detected.  For example, use of a paced 
puffing procedure was necessary to standardize puffs across formulations, but did not 
likely engender puff topographies present in the natural ecology.  Puff topographies used 
in the natural ecology may engender subjective effects associated with these ingredients 
that were not detectable with the standardized puffs used in this study.  Also, use of 
certain EC parameters (e.g. wattage) may not have been optimal for detecting differences 
in PG/VG cue effects, and differences in these ingredients may become more apparent at 
different power levels.  Another possible reason for these disparate results could be the 
context under which cues were measured; the survey study prompted participants to use 
unblinded and potentially biased experience with PG and VG in reporting cue effects, 
whereas cue effects were engendered by formulations presented under double-blind 
conditions in the laboratory study.  In the natural ecology perceptions of PG and VG 
effects could be shaped by outside stimuli (e.g. peer influences) and expectation effects 
(e.g. preconceived notions that PG or VG are associated with certain effects).  In the 
laboratory study, however, participants were not informed that PG and VG were being 
manipulated, and therefore potential biases were controlled.  Another possibility is that 
the format of the self-report measures contributed to the discrepancy between these 
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studies.  In the survey study participants were asked to rate how closely associated PG 
and VG are to several subjective effects on a 100-point slider, anchored with PG on one 
end, and VG on the other.  In the laboratory study participants were given a 100-point 
slider for each subjective effect, anchored with ‘not at all’ on one end, and ‘extremely’ on 
the other.  Lastly, it is possible that critical cue effects relevant to PG and VG in EC 
liquids were not comprehensively assessed.  Although the subjective effect measures 
were carefully selected from previous research, future studies may consider using a 
mixed methods approach to examine stimulus effects following double-blinded 
presentation of formulations with varying amounts of PG and VG to examine the 
spectrum of potential cues produced by PG and VG in EC liquids.   
3.4.1 Conclusion 
These data suggest VG has a greater effect on the visibility of exhalant (i.e. cloud) 
compared to PG, and equal mixtures of PG/VG are better at producing inhalation 
sensations similar to conventional cigarettes.  Neither ingredient was related to 
reinforcing effects (e.g. liking; Figure 3.7), but the formulations used in the current study, 
devoid of flavorants, had little monetary value.   
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Table 3.1 Laboratory Study Test Day Schedule 
Time 
(min) Study Activity 
0 Pre-session questionnaire, field sobriety test, snack provided, breath 
analyses, urinary analyses, pre-administration measures, heart rate and blood 
pressure measured 
30 
35 
95 
96 
97 
102 
115 
116 
117 
122 
10-puffs administered 
One-hour deprivation period 
Pre-administration measures 
Two sample puffs administered                              1st choice procedure 
Post-administration measures 
Two-more puffs administered (if applicable) 
Pre-administration measures 
Two sample puffs administered                              2nd choice procedure 
Post-administration measures        
Two-more puffs administered (if applicable) 
…Choice procedures repeated until all five are finished…
180 
210 
30 min waiting period 
Field sobriety test and participant paid and allowed to leave the laboratory 
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Table 3.2 Demographic and Clinical Variables 
N=16 
Age, mean (SD) 24.8 (3.65) 
Sex, N (%) 
  Male 
  Female 
12 (75.0) 
4 (25.0) 
mFTND Score, mean (SD) 14.8 (3.8) 
Typical electronic cigarette nicotine concentration (mg/ml), mean (SD) 7.13 (5.2) 
Typical electronic cigarette nicotine wattage, mean (SD) 64.5 (33.4) 
Milligrams of electronic cigarette liquid per day, mean (SD) 6.6 (7.5) 
Years of electronic cigarette use, mean (SD) 2.7 (1.8) 
Use of other tobacco products in the past month 
  Conventional Tobacco Cigarettes, N (%) 
  Chewing Tobacco 
  Hookah 
2 (12.5) 
1 (6.3) 
1 (6.3) 
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Table 3.3 Results of mixed models for all laboratory measures 
F 
Linear 
Post-Hoc 
Quadratic 
Post-Hoc 
CONTROL MEASURES 
  Visual Analog Scale – Smoking Effects 
  Do you feel confused?  — — — 
  Do you feel dizzy?  — — — 
  Do you feel headache?  — — — 
  Do you feel heart pounding?  — — — 
  Do you feel lightheaded?  — — — 
  Do you feel nauseous?  — — — 
  Do you feel nervous?  — — — 
  Do you feel salivation?  — — — 
  Do you feel sweaty?  — — — 
  Do you feel weak? — — — 
  Do you feel stimulated? — — — 
  Puff Topography 
  Per Puff Volume — — — 
  Per Puff Duration — — — 
  Physiological Measures 
  Heart rate — — — 
  Diastolic blood pressure — — — 
  Systolic blood pressure 3.67* — 12.66** 
  Questionnaire of Smoking Urges - Brief 
  I have a desire for an electronic cigarette right now. — — — 
  Nothing would be better than using an electronic cigarette 
     right now. — — — 
  If it were possible I would probably use an electronic 
     cigarette now. — — — 
  I could control things better right now if I could use an 
     electronic cigarette. — — — 
  All I want right now is to use an electronic cigarette. — — — 
  I have an urge for an electronic cigarette. — — — 
  An electronic cigarette would taste good now.  — — — 
  I would do almost anything or an electronic cigarette now. — — — 
  Using an electronic cigarette would make me less depressed. — — — 
  I am going to use an electronic cigarette as soon as possible. — — — 
OUTCOME MEASURES 
Multiple Choice Procedure 
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    Breakpoint — — — 
Duke Sensory Questionnaire      
    How much nicotine do you estimate was in the last puffs? 3.05* — 6.20* 
    How similar were those puffs to your typical electronic  
       cigarette? — — — 
    What was the strength of the puffs on your tongue? 3.98** — 9.78* 
    What was the strength of the puffs in your nose?  — — — 
    What was the strength of the puffs in the back of your mouth  
       and throat?  2.91* — — 
    What was the strength of the puffs in your windpipe? 3.09* — — 
    What was the strength of the puffs in your chest? 3.52* — 5.16* 
  Visual Analog Scale – Post Smoking    
    Do you like the effects? — — — 
    Do you want to use the electronic cigarette again? — — — 
    Did you enjoy the electronic cigarette? — — — 
    Do you crave the electronic cigarette? — — — 
    Did the electronic cigarette produce a large vapor cloud? 2.77* 10.59** — 
    Did you experience a throat hit? 3.43* — 7.66* 
    Do you feel dry mouth? — — — 
    Do you feel sore throat? — — — 
    Did you enjoy the smell? — — — 
    Did you enjoy the taste? — — — 
    Did you dislike the effects? — — — 
 *=p<.05, **=p<.01, ‘—' = statistic not significant  
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Figure 3.1 Changes in systolic blood pressure 
Change in systolic blood pressure from baseline to following two-puff bouts.  A significant quadratic relationship between 
formulations was indicated (F[55]=12.66, p<.001) 
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Figure 3.2 Ratings of “how much nicotine do you estimate was in the last puffs?” 
Ratings of “how much nicotine do you estimate in the last puffs” following two-puff bouts.  A significant quadratic relationship 
between formulations was indicated (F[60]=6.2, p=.016). 
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Figure 3.3 Ratings of “what was the strength of the puffs in your chest?”
Ratings of “what was the strength of the puffs in your chest” following two-puff bouts.  A significant quadratic relationship between 
formulations was indicated (F[60]=5.16, p=.027). 
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Figure 3.4 Ratings of “did the electronic cigarette produce a large cloud?” and “what was the strength of the puffs on your tongue?” 
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Ratings of ‘did the electronic cigarette produce a large cloud’ on a 100-point visual analog scale (left) and “what was the strength of 
the puffs on your tongue” (right).  Values represent least-squares mean estimates and standard error bars derived from the mixed 
model.  A significant main effect of liquid condition was indicated on “large cloud” (F[60]=2.77, p=.035) and post-hoc tests indicated 
a significant linear relationship (F[60]=10.59, p=.002).  A significant main effect of liquid condition was indicated on “strength on 
the tongue” (F[60]=3.98, p=.006) and post-hoc tests indicated a significant quadratic relationship (F[60]=9.78, p=.003). 
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Figure 3.5 Ratings of “did you experience a throat hit?” 
Ratings of “did you experience a throat hit” following two-puff bouts.  A significant quadratic relationship between formulations was 
indicated (F[60]=7.66, p=.008). 
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Figure 3.6 Breakpoint on the Multiple-Choice Procedure
Breakpoints between money and two-more puffs, as measured by the multiple-choice procedure.  There were no significant 
differences among liquid formulations.   
$0.00
$0.50
$1.00
100/0% 75/25% 50/50% 25/75% 0/100%
Br
ea
kp
oi
nt
VG PG
56  
Figure 3.7 Ratings of “do you like the effects?” of the puff 
Ratings of “do you like the effects” following two-puff bouts.  There were no significant differences among liquid formulations. 
0
20
40
60
80
100
100/0% 75/25% 50/50% 25/75% 0/100%
VA
S 
Va
lu
e
PGVG 
 57 
CHAPTER FOUR: OVERALL DISCUSSION 
This dissertation examined the effects of PG and VG on the abuse liability of ECs 
by collecting self-reported perceptions of EC users in an online survey, and by using 
gold-standard measures of abuse liability in a laboratory study.  The results of the survey 
indicated that EC users associate PG with undesirable effects, while VG is associated 
with desirable effects.  With the exception of “large cloud” being associated with 
formulations containing greater amounts of VG and “throat hit” being more closely 
associated with a mixture of PG and VG (Figure 3.5), these user perceptions were not 
consistent with subjective effects observed in the laboratory study under controlled, 
double-blind conditions in the absence of taste cues.  Other sensations typically 
associated with CCs (i.e. estimates of nicotine in the puffs [Figure 3.2], and strength of 
the puffs on the tongue [Figure 3.4] and in the chest [Figure 3.3]) were associated with 
mixtures of PG and VG, which may suggest that mixtures of PG and VG have greater 
liability for abuse compared to PG or VG alone among individuals who are former or 
current CC users.  Yet, since subjective effects typically associated with abuse liability 
(e.g. ‘liking’ [Figure 3.7]) were not associated with PG or VG concentrations and of 
small magnitude under the limited conditions in which significant effects were observed, 
these data provide evidence that PG and VG have minimal impact of the reinforcing 
efficacy of ECs under the testing conditions in the laboratory study.  In the absence of 
any taste cues, however, the aerosols produced by the ECs used in the laboratory study 
were not reinforcing according to the MCP (Figure 3.6).  Due to the lack of clear 
reinforcing effects of the aerosols in this study, future research should examine possible 
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differences in reinforcing effects of PG and VG when taste cues are included in the EC 
aerosol conditions. 
Although PG and VG did not significantly influence typical measures of liability 
for abuse (see Table 3.3), results of the survey and laboratory study may provide some 
insights on the perhaps modest influence of PG and VG liquid concentrations on liability 
for abuse.  Subjective reports of ‘large cloud’ were perceived as being related to VG in 
the survey and positively correlated with amount of VG in the EC liquid in the laboratory 
study.  Visibility of the exhalant may be an important effect for many EC users, and 
particularly individuals who are transitioning from CCs to ECs.  From a smoking 
cessation perspective, the more closely ECs match the stimulus characteristics of CCs, 
the more likely they are to be effective as smoking cessation tools.  Thus, because visible 
smoke emission is a stimulus associated with CCs, mimicking this stimulus may increase 
smoking cessation efficacy of ECs.  Many EC users are also enthusiasts about creating 
large clouds (Chu et al., 2016), and among this population VG may increase the abuse 
liability of EC liquids. 
In the laboratory study greater reports of “strength on the tongue” and other 
common CC smoking sensations were associated with mixtures of PG and VG as 
opposed to PG or VG alone, which may also have an effect on abuse liability among 
some EC users.  Also, survey respondents did not report PG or VG being more closely 
related to throat hit, which is consistent with these laboratory study data.  Nicotine 
concentration was, however, positively correlated with throat hit in the survey study.  
With this in mind, EC users may be able to obtain greater throat hit by optimizing PG and 
VG ratios, increasing liquid nicotine concentrations, or both.  Though, it should be 
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emphasized that the effects on throat hit among PG and VG formulations in the 
laboratory study were modest.  Nonetheless, from a smoking cessation perspective, use of 
mixtures of PG and VG may increase efficacy of ECs for smoking cessation among 
individuals placing importance on common CC sensations, or if they are trying to mimic 
the effects of a CC.  Alternatively, abuse liability of ECs may be increased among 
individuals with a significant CC use history when mixtures of PG and VG are used 
because of its ability to increase throat hit and other CC smoking sensations.  Since it 
could be speculated that history of CC use is an important factor when considering 
similarity of EC sensations to CCs, future research may wish to examine populations of 
never CC users compared to current or previous CC users to study the importance of 
these sensations between these groups. 
The intention of the laboratory study was to examine the stimulus effects of EC 
liquids, while avoiding significant plasma nicotine accumulation, so small puffing bouts 
(i.e. two-puffs) were used for each formulation to avoid significant delivery of nicotine 
while still allowing stimulus effects not mediated by the central nervous system (CNS) to 
be experienced.  Therefore, the current study was not designed to detect differences in 
nicotine delivery among PG and VG concentrations.  As such, expectedly, there were no 
significant differences among PG and VG concentrations on control measures (i.e. 
prototypical nicotine effects, Table 3.3).  Some research mentioned previously (Yan and 
D’Ruiz, 2015; Baassiri et al., 2017) has suggested that PG and VG in EC liquids would 
have an impact on nicotine delivery, potentially by altering nicotine content in EC 
aerosols.  With this in mind, future studies focusing on differences in prototypical 
nicotine effects and plasma nicotine concentrations are warranted.  For example, it is 
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possible future research studies using larger puffing bouts, which would engender 
significant plasma nicotine concentrations, may find significant differences on 
prototypical nicotine effects.  Though the laboratory study design was not intended to 
induce significant effects of nicotine in the CNS, if PG and VG caused differential 
amount of nicotine in the aerosol, this could alter stimulus characteristics not mediated by 
the CNS.  Past research, for example, has shown differing stimulus effects from de-
nicotinized CCs paired with intravenously administered nicotine vs smoking a CC with 
nicotine (Westman et al., 1996), indicating that nicotine alters stimulus effects not 
associated with CNS activity (e.g. inhalation sensations).  As such, results from the 
laboratory study might suggest that differences observed in CC like smoking sensations 
are due to differences in aerosol nicotine concentration across PG and VG formulations.  
Research looking directly at this possibility is, however, necessary to determine if aerosol 
nicotine concentration is the mechanism mediating CC like smoking sensations.   
There are several possible explanations for the disparity between perceptions of 
PG and VG effects in the survey study and results of the laboratory study.  The survey 
study indicates that EC parameters are utilized heterogeneously among users, and it is 
possible that PG and VG effects differ as a function of parameter settings.  Supporting 
this idea, Talih and colleagues (2017) used machine puffing to demonstrate that presence 
of PG or VG in aerosol emissions varies depending on EC power, suggesting there would 
be an interacting influence of power and concentration of PG and VG in EC liquids on 
subjective effects.  Another possibility is that amount of PG and VG in liquids is 
correlated with inclusion of specific flavorants, such that perceptions of PG and VG 
interact with effects of other flavorants.  With this in mind, future research examining 
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ingredients of EC liquids may want to explore this possibility.  Lastly, it could simply be 
that EC users have developed perceptions of PG and VG that are based on inaccurate 
anecdotal reports that have perpetuated throughout the community.     
In the laboratory study the reinforcing effects of all formulations of PG and VG 
were minimal, such participants often chose $0.00 over two more puffs of any of the 
formulations (Figure 3.6).  This could be because the MCP is not sensitive enough to 
detect the perhaps modest reinforcing effects of the ECs used under the conditions of this 
study.  Although much previous research has shown that the MCP is an effective way to 
measure the reinforcing effects of drugs of abuse in a laboratory setting (e.g. Griffiths et 
al., 1993, Griffiths et al., 1996, Vansickel et al., 2012), the MCP has not always been 
effective at detecting reinforcing effects of drugs with well-known abuse liability (e.g. 
Rush et al., 1999).  It is also possible that a lack of a strong signal on the MCP in the 
laboratory study was due to a lack of flavoring in the EC liquids.  In support of this, many 
participants in the laboratory study spontaneously reported that the taste of these 
formulations was not desirable and, as indicated in the survey study, most EC users rate 
taste as the most important factor when selecting EC liquids.  Thus, these results may 
further suggest that the addition of flavorants in liquids is a major contributor to the 
reinforcing effects of EC liquids.  As of yet, no other published research has examined 
the reinforcing effects of unflavored liquids in ECs.  As such, though there are many 
parameters that may have affected the reinforcing effects of the liquids in this study (e.g. 
the relatively short period of nicotine deprivation, the EC parameters used), further 
research could begin evaluating the reinforcing effects of flavorants added to EC liquids.   
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It could be speculated that utilizing liquids with added flavorants may have been a 
more effective approach to measuring the effects of PG and VG in the laboratory study.  
Yet, while including flavorants into the liquids may have increased reinforcing effects, it 
would have hampered interpretation of the study results for two reasons: 1) participants 
would likely have had different preferences for flavorings, and addition of one kind of 
flavor profile may have only increased reinforcing effects of the EC liquids for some 
participants – or potentially decreased reinforcing effects for others – and 2) flavorants 
may interact with PG and VG, and therefore obfuscate the reinforcing effects of PG and 
VG, which is supported by previous research demonstrating that flavorants can modulate 
the sensory effects of PG and VG (Rao et al., 2017).  Though the addition of flavorants 
may not be optimal for a controlled study, future research looking to study reinforcing 
effects of PG and VG may benefit from developing a more acceptable aerosol than that 
used in this laboratory study.  Aside from flavoring, since previous research has shown 
that reinforcing effects of nicotine are positively correlated with previous cigarette 
consumption (i.e. nicotine deprivation; Rose et al., 1984), using a longer deprivation 
period than the current study (i.e. 1 h) would also likely increase the reinforcing effects of 
EC liquids in a laboratory study.  In addition to recency of previous EC use, availability 
of the next sample puffs may have reduced reinforcing effects of the liquids in this study, 
and therefore extending periods between bouts (i.e. > 20 min) might increase reinforcing 
effects of puffs in future studies.  Lastly, puffing procedures in the current study were 
controlled to standardize dosage between formulations and participants.  Constrained 
puffing behavior, however, may have engendered lesser reinforcing effects of the EC 
compared to an ad-lib puffing procedure, and therefore future studies may wish to 
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incorporate ad-lib puffing procedure when attempting to measure reinforcing effects of 
ECs.   
In the context of this dissertation, the survey study was conducted primarily to 
provide insight on EC users’ perceptions of PG and VG, and to determine what 
parameters (e.g. liquid nicotine concentration and wattage levels) are preferred by regular 
EC users.  Unexpected, yet interesting, findings from this survey were the proportion of 
individuals who indicated not attending to common EC parameters, and the variability in 
parameter settings.  Only 57.7% of individuals reported knowing the wattage of their 
device, and only 70.1% reported knowing the nicotine concentration of the liquids they 
typically use.  Even still, among those who reported these parameters, there is a wide 
distribution of settings (Figure 2.3).  These data underscore the challenges researchers 
face when attempting to identify devices and settings for use in laboratory studies that 
will produce results that are generalizable to the natural ecology.  Recently the National 
Institute on Drug Abuse began offering the Standardized Research Electronic Cigarette 
(SREC) in an attempt to standardize ECs used in research.  This device functions at a 
power level of 9 watts, and is offered with unflavored or tobacco flavored liquids 
containing 0 or 15 mg/ml nicotine concentration and 50/50% PG/VG.  Use of this device 
in research and interpretation of results generated with it, however, must be done 
cautiously.  Since it is known that EC parameters are used at many different settings, it is 
possible that results produced with the SREC will have limited generality.  Use of the 
unflavored SREC liquid, for example, may be problematic because – as data in the 
laboratory study conducted here demonstrate – unflavored liquids may not be reinforcing 
under certain conditions.  Lastly, since taste was indicated as the most important factor 
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when selecting EC liquids, availability of only one type of flavored liquid (i.e. tobacco 
flavor) may limit reinforcing efficacy of the SREC to certain populations.  As such, 
future research may want to examine the reinforcing efficacy of the SREC in comparison 
to other ECs, and particularly its comparison to research participants’ preferred ECs.   
In conclusion, the results of this dissertation inform future research by 
demonstrating perceptions of PG and VG among the EC using community and testing the 
effects of PG and VG in a carefully controlled laboratory study.  Future research on ECs 
should be mindful that, while PG and VG may not have significant effects on the abuse 
liability of ECs in the absence of flavorants, these ingredients can cause significant 
differences on several stimulus effects, which should be accounted for when selecting 
liquids for research.  Also, future research efforts should note that omission of flavorants 
in EC liquids may reduce reinforcing effects of ECs, such that measures of these effects 
may not produce generalizable data.  Lastly, PG and VG may not be an important 
regulatory target from an abuse liability perspective because they did not significantly 
differ on typical abuse liability measures in the laboratory study, however, future research 
will be required to more comprehensively study PG and VG among different populations 
and among different EC settings.   
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